Literature DB >> 8380095

Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.

J K Yamamoto1, T Hohdatsu, R A Olmsted, R Pu, H Louie, H A Zochlinski, V Acevedo, H M Johnson, G A Soulds, M B Gardner.   

Abstract

More than 90% of cats immunized with inactivated whole infected-cell or cell-free feline immunodeficiency virus (FIV) vaccines were protected against intraperitoneal infection with 10 50% animal infectious doses of either homologous FIV Petaluma (28 of 30 cats) or heterologous FIV Dixon strain (27 of 28 cats). All 15 control cats were readily infected with either strain of FIV. Protection appears to correlate with antiviral envelope antibody levels by a mechanism yet to be determined.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8380095      PMCID： PMC237403     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  15 in total

1.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Anti-cell antibody in macaques.

Authors:  E J Stott
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

Review 3.  SIV vaccines, 1991--a year in review.

Authors:  M B Gardner; S L Hu
Journal:  AIDS       Date:  1991       Impact factor: 4.177

Review 4.  Feline immunodeficiency virus as a model for AIDS vaccination.

Authors:  O Jarrett; J K Yamamoto; J C Neil
Journal:  AIDS       Date:  1990       Impact factor: 4.177

5.  Experimental vaccine protection against feline immunodeficiency virus.

Authors:  J K Yamamoto; T Okuda; C D Ackley; H Louie; E Pembroke; H Zochlinski; R J Munn; M B Gardner
Journal:  AIDS Res Hum Retroviruses       Date:  1991-11       Impact factor: 2.205

6.  Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.

Authors:  N E Byars; A C Allison
Journal:  Vaccine       Date:  1987-09       Impact factor: 3.641

Review 7.  Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.

Authors:  M B Gardner
Journal:  Antiviral Res       Date:  1991-05       Impact factor: 5.970

8.  Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines.

Authors:  J K Yamamoto; C D Ackley; H Zochlinski; H Louie; E Pembroke; M Torten; H Hansen; R Munn; T Okuda
Journal:  Intervirology       Date:  1991       Impact factor: 1.763

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies.

Authors:  T Hohdatsu; M Nakamura; Y Ishizuka; H Yamada; H Koyama
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574
View more
  31 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

Review 5.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.

Authors:  S Lombardi; C Garzelli; C La Rosa; L Zaccaro; S Specter; G Malvaldi; F Tozzini; F Esposito; M Bendinelli
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.